Everolimus in the treatment of metastatic breast cancer

Breast Cancer: Basic and Clinical Research

Volumn 9, Issue , 2015, Pages 73-79

  Royce, Melanie E ^a   Osman, Diaa ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Endocrine resistance; Everolimus; Hormone receptor positive; mTOR

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; NAVELBINE; PACLITAXEL; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADVERSE OUTCOME; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL STUDY; DECREASED APPETITE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HUMAN; HYPERGLYCEMIA; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; TREATMENT RESPONSE;

EID: 84940977806     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S29268     Document Type: Article

References (41)

1. Germano S, O’Driscoll L. Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr Cancer Drug Targets. 2009;9:398–418.
2. Pritchard KI. Endocrine therapy: is the first generation of targeted drugs the last? J Intern Med. 2013;274:144–152.
3. Zardavas D, Fumagalli D, Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers? Curr Opin Oncol. 2012;24:623–634.
4. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231–1241.
5. Mayer I. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol. 2013;11:217–224.
6. Lebwohl D, Thomas G, Lane HA, et al. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov. 2011;6:323–338.
7. Anandappa G, Hollingdale A, Eisen T. Everolimus—a new approach in the treatment of renal cell carcinoma. Cancer Manag Res. 2010;2:61–70.
8. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009;27:4536–4541.
9. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–529.
10. Novartis Pharmaceuticals Corporation. Afinitor (everolimus) tablets for oral administration [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
11. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2. Fort Washington: NCCN; 2015.
12. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progressionfree survival analysis. Adv Ther. 2013;30:870–884.
13. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25:2357–2362.
14. Pritchard KI, Burris HA III, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013; 13:421–432.
15. Noguchi S, Masuda N, Iwata H, et al. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormonereceptor-positive breast cancer in BOLERO-2. Breast Cancer. 2014;21:703–714.
16. Campone M, Bachelot T, Gnant M, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer. 2013;49: 2621–2632.
17. Beck JT, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR, HER2 advanced breast cancer in BOLERO-2. Breast Cancer Res Treat. 2014;143:459–467.
18. Burris HA III, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane ve rsus placeboplus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013;119:1908–19115.
19. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012; 30:2718–2724.
20. Massarweh S, Romond E, Black EP, et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat. 2014; 143:325–332.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.
22. Mohd Sharial MS, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol. 2012;23: 3007–3016.
23. Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007;13:5883–5888.
24. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–127.
25. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402.
26. Miller TW, Forbes JT, Shah C, et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res. 2009;15:7266–7276.
27. Andre F, Campone M, O’Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010;28:5110–5115.
28. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2011; 125:447–455.
29. Andre F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumabresistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580–591.
30. Hurvitz SA, Andre F, Jiang Z, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16:816–29.
31. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–1728.
32. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304–311.
33. Singh J, Novik Y, Stein S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res. 2014;16:32.
34. Gonzalez-Angulo AM, Akcakanat A, Liu S, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol. 2014;25:1122–1127.
35. Novartis Pharmaceuticals. Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+, HER2-metastatic or locally advanced breast cancer (Bolero-4). Bethesda, MD: National Library of Medicine (US); 2000 [cited April 22, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT01698918. [NLM Identifier: NCT01698918].
36. PrECOG LLC. Study of fulvestrant +/- everolimus in post-menopausal, hormonereceptor+metastatic breast Ca resistant to AI (PrE0102). Bethesda, MD: National Library of Medicine (US); 2000 [cited April 22, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT01797120?term=Study+of+Fulvestrant+%2B%2F-+Everolimus+in+Post-Menopausal%2C+Hormone-Receptor+%2B+Metastatic+Breast+Ca+Resistant+to+AI&rank=1. [NLM Identifier: NCT01797120].
37. Janni W. DETECT IV—a study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Bethesda, MD: National Library of Medicine (US); 2000 [cited April 22, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT02035813. [NLM Identifier:NCT02035813].
38. Southwest Oncology Group. S1207 hormone therapy with or without everolimus in treating patients with breast cancer (e3). Bethesda, MD: National Library of Medicine (US); 2000 [cited April 22, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT01674140?term=S1207+Hormone+Therapy+With+or+Without+Everolimus+in+Treating+Patients+With+Breast+Cancer&rank=1. [NLM Identifier: NCT01674140].
39. SCRI Development Innovations LLC. Trial of paclitaxel/bevacizumab +/-everolimus for patients with HER2-negative metastatic breast cancer. Bethesda, MD: National Library of Medicine (US); 2000 [cited April 22, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT00915603?term=Trial+of+Paclitaxe l%2FBevacizumab+%2B%2F-+Everolimus+for+Patients+With+HER2-Negati ve+Metastatic+Breast+Cancer&rank=1. [NLM Identifier: NCT00915603].
40. Vanderbilt-Ingram Cancer Center. Cisplatin and paclitaxel with or without everolimus in treating patients with stage II or stage III breast cancer. Bethesda, MD: National Library of Medicine (US); 2000 [cited April 22, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT00930930?term=Cisplatin+and+Paclitaxel+With+or+Without+Everolimus+in+Treating+Patients+With+Stage+II+or+Stage+III+Breast+Cancer&rank=1. [NLM Identifier: NCT00930930].
41. AIO-Studien-gGmbH. Study to compare vinorelbine in combination with the mTOR inhibitor everolimus vs vinorelbin monotherapy for second-line treatment in advanced breast cancer (VicTORia). Bethesda, MD: National Library of Medicine (US); 2000 [cited April 22, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT01520103?term=Study+to+Compare+Vinorelbine+In+Combination+With+the+mTOR+Inhibitor+Everolimus+vs.+Vinorelbin+Monot herapy+for+Second-line+Treatment+in+Advanced+Breast+Cancer&rank=1. [NLM Identifier: NCT01520103].